Long COVID was diagnosed at 6 months in 19% in the molnupiravir group and 22% in the no-treatment group.
Molnupiravir tied to lower risk of long COVID in high-risk patients
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- Global, US data show high antibiotic use, rise in resistant infections during COVID
- US respiratory virus levels continue to decline as officials track shift in SARS-CoV-2 proportions
- Study reveals promising results for abatacept for severe COVID
- Long-COVID patients more likely to report psychiatric symptoms, cost barriers to therapy